BACKGROUND: This study examined patterns of medication compliance and reasons for noncompliance among patients with bipolar disorder and substance use disorder. METHOD: Forty-four patients with current bipolar disorder and substance use disorder were administered a structured interview regarding lifetime compliance with prescribed psychotropic medications. RESULTS: Patients who were prescribed both lithium and valproate were significantly (p = .03) more likely to report full compliance with valproate than with lithium. Side effects were the most common reason for lithium noncompliance, but were not cited as a reason for valproate noncompliance. Also, a common pattern of noncompliance among patients prescribed benzodiazepines, neuroleptics, and tricyclic antidepressants was the use of more medication than prescribed. CONCLUSION: Valproate may have greater acceptability than lithium among patients with bipolar disorder and substance use disorder. Clinicians should also be aware that these patients may take higher doses of medication than prescribed.
BACKGROUND: This study examined patterns of medication compliance and reasons for noncompliance among patients with bipolar disorder and substance use disorder. METHOD: Forty-four patients with current bipolar disorder and substance use disorder were administered a structured interview regarding lifetime compliance with prescribed psychotropic medications. RESULTS:Patients who were prescribed both lithium and valproate were significantly (p = .03) more likely to report full compliance with valproate than with lithium. Side effects were the most common reason for lithium noncompliance, but were not cited as a reason for valproate noncompliance. Also, a common pattern of noncompliance among patients prescribed benzodiazepines, neuroleptics, and tricyclic antidepressants was the use of more medication than prescribed. CONCLUSION:Valproate may have greater acceptability than lithium among patients with bipolar disorder and substance use disorder. Clinicians should also be aware that these patients may take higher doses of medication than prescribed.
Authors: David A Smelson; Lisa Dixon; Thomas Craig; Stephen Remolina; Steven L Batki; Noosha Niv; Richard Owen Journal: CNS Drugs Date: 2008 Impact factor: 5.749
Authors: Benjamin I Goldstein; Tina R Goldstein; Katelyn A Collinger; David A Axelson; Oscar G Bukstein; Boris Birmaher; David J Miklowitz Journal: J Psychiatr Pract Date: 2014-05 Impact factor: 1.325
Authors: L G Sylvia; N A Reilly-Harrington; A C Leon; C I Kansky; J R Calabrese; C L Bowden; T A Ketter; E S Friedman; D V Iosifescu; M E Thase; M J Ostacher; M Keyes; D Rabideau; A A Nierenberg Journal: Acta Psychiatr Scand Date: 2013-10-03 Impact factor: 6.392
Authors: Susan J Wenze; Michael F Armey; Lauren M Weinstock; Brandon A Gaudiano; Ivan W Miller Journal: J Psychiatr Pract Date: 2016-11 Impact factor: 1.325
Authors: Douglas M Ziedonis; David Smelson; Richard N Rosenthal; Steven L Batki; Alan I Green; Renata J Henry; Ivan Montoya; Joseph Parks; Roger D Weiss Journal: J Psychiatr Pract Date: 2005-09 Impact factor: 1.325
Authors: Benjamin I Goldstein; Michael A Strober; Boris Birmaher; David A Axelson; Christianne Esposito-Smythers; Tina R Goldstein; Henrietta Leonard; Jeffrey Hunt; Mary Kay Gill; Satish Iyengar; Colleen Grimm; Mei Yang; Neal D Ryan; Martin B Keller Journal: Bipolar Disord Date: 2008-06 Impact factor: 6.744
Authors: Martha Sajatovic; Rosalinda V Ignacio; Jane A West; Kristin A Cassidy; Roknedin Safavi; Amy M Kilbourne; Frederic C Blow Journal: Compr Psychiatry Date: 2008-08-23 Impact factor: 3.735